Minneapolis
89°F
eEdition
News & Politics
Sports
Food & Culture
Business
Outdoors
Opinion
Things To Do
Obituaries
More of What Matters to Minnesota
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Minnesota State Top Stocks
Markets
Minnesota Stocks
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Therapeuticsmd Inc
(NQ:
TXMD
)
1.890
+0.120 (+6.78%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Therapeuticsmd Inc
< Previous
1
2
Next >
TherapeuticsMD Announces Second Quarter 2024 Financial Results
August 12, 2024
From
TherapeuticsMD, Inc.
Via
Business Wire
TherapeuticsMD Announces First Quarter 2024 Financial Results
May 10, 2024
From
TherapeuticsMD, Inc.
Via
Business Wire
TherapeuticsMD Announces Full Year 2023 Financial Results
March 29, 2024
From
TherapeuticsMD, Inc.
Via
Business Wire
TherapeuticsMD Announces Third Quarter 2023 Financial Results
November 14, 2023
From
TherapeuticsMD, Inc.
Via
Business Wire
TherapeuticsMD Announces Second Quarter 2023 Financial Results
August 14, 2023
From
TherapeuticsMD, Inc.
Via
Business Wire
TherapeuticsMD Announces First Quarter 2023 Financial Results
May 15, 2023
From
TherapeuticsMD, Inc.
Via
Business Wire
TherapeuticsMD Announces Full Year 2022 Financial Results and Provides Update on Business Model Transition
April 07, 2023
From
TherapeuticsMD, Inc.
Via
Business Wire
TherapeuticsMD Completes Transaction to License Its Products to Mayne Pharma
January 03, 2023
From
TherapeuticsMD, Inc.
Via
Business Wire
TherapeuticsMD Announces Definitive Agreements to License its Products to Mayne Pharma
December 04, 2022
From
TherapeuticsMD, Inc.
Via
Business Wire
TherapeuticsMD Announces Third Quarter 2022 Financial Results
November 14, 2022
From
TherapeuticsMD, Inc.
Via
Business Wire
TherapeuticsMD Announces Additional $7 Million Private Placement
October 31, 2022
From
TherapeuticsMD, Inc.
Via
Business Wire
TherapeuticsMD Announces $7 Million Private Placement
October 03, 2022
From
TherapeuticsMD, Inc.
Via
Business Wire
TherapeuticsMD Appoints Dr. Brian Bernick and Mr. Mark Glickman as Interim Co-Chief Executive Officers
September 12, 2022
From
TherapeuticsMD, Inc.
Via
Business Wire
TherapeuticsMD Announces Second Quarter 2022 Financial Results
August 15, 2022
From
TherapeuticsMD, Inc.
Via
Business Wire
TherapeuticsMD to Report Second Quarter 2022 Financial Results on August 15, 2022
August 08, 2022
From
TherapeuticsMD, Inc.
Via
Business Wire
TherapeuticsMD Secures $15 Million Equity Investment from Rubric Capital
August 01, 2022
From
TherapeuticsMD, Inc.
Via
Business Wire
TherapeuticsMD Announces Expiration of Tender Offer
July 13, 2022
From
TherapeuticsMD, Inc.
Via
Business Wire
THERAPEUTICSMD INVESTOR ALERT by The Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of TherapeuticsMD, Inc. - TXMD
May 31, 2022
From
Kahn Swick & Foti, LLC
Via
Business Wire
TXMD Stock Alert: Halper Sadeh LLP Is Investigating Whether the Sale of TherapeuticsMD, Inc. Is Fair to Shareholders
May 31, 2022
From
Halper Sadeh LLP
Via
Business Wire
TherapeuticsMD and EW Healthcare Partners Announce Definitive Agreement for EW Healthcare Partners to acquire TherapeuticsMD
May 31, 2022
From
TherapeuticsMD, Inc.
Via
Business Wire
TherapeuticsMD Receives U.S. Food and Drug Administration (FDA) Approval for Supplemental New Drug Application (sNDA) for ANNOVERA®
May 20, 2022
From
TherapeuticsMD, Inc.
Via
Business Wire
TherapeuticsMD Announces First Quarter 2022 Financial Results
May 16, 2022
From
TherapeuticsMD, Inc.
Via
Business Wire
TherapeuticsMD to Report First Quarter 2022 Financial Results on May 16, 2022
May 10, 2022
From
TherapeuticsMD, Inc.
Via
Business Wire
TherapeuticsMD Completes the Divestiture of vitaCare Prescription Services to GoodRx in a Cash Transaction Valued at $150 Million
April 14, 2022
From
TherapeuticsMD, Inc.
Via
Business Wire
U.S. Food and Drug Administration (FDA) Responds to Request From TherapeuticsMD to Revise Certain Manufacturing Testing Limits for ANNOVERA®
December 10, 2021
From
TherapeuticsMD, Inc.
Via
Business Wire
TherapeuticsMD Settles U.S. Patent Litigation with Amneal for BIJUVA® (Estradiol and Progesterone) — Allowing for a May 25, 2032 Generic Entry Date
December 08, 2021
From
TherapeuticsMD, Inc.
Via
Business Wire
TherapeuticsMD Announces Third Quarter 2021 Financial Results
November 11, 2021
From
TherapeuticsMD, Inc.
Via
Business Wire
TherapeuticsMD Announces Leadership Changes; Appointment of Industry Veteran, Hugh O’Dowd, as Chief Executive Officer
November 11, 2021
From
TherapeuticsMD, Inc.
Via
Business Wire
TherapeuticsMD to Report Third Quarter 2021 Results on November 11, 2021
October 27, 2021
From
TherapeuticsMD, Inc.
Via
Business Wire
TherapeuticsMD Announces Appointment of Mark Glickman as Chief Business Officer
October 15, 2021
From
TherapeuticsMD, Inc.
Via
Business Wire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.